953039-61-7

Basic information

• Product Name: Benzaldehyde, 2-amino-3-bromo-5-fluoro-
• Synonyms: Benzaldehyde, 2-amino-3-bromo-5-fluoro-;2-Amino-3-bromo-5-fluoro-benzaldehyde
• CAS NO: 953039-61-7
• Molecular Formula: C7H5BrFNO
• Molecular Weight: 218.0231032
• Mol File: 953039-61-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 291.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.761±0.06 g/cm3(Predicted)
• PKA: -1.53±0.10(Predicted)
• CAS DataBase Reference: Benzaldehyde, 2-amino-3-bromo-5-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 2-amino-3-bromo-5-fluoro-(953039-61-7)
• EPA Substance Registry System: Benzaldehyde, 2-amino-3-bromo-5-fluoro-(953039-61-7)

Safety Data

• Hazardous Substances Data: 953039-61-7(Hazardous Substances Data)

Upstream product

• 446-08-2 2-amino-5-fluorobenzoic acid 
• 259269-84-6 2-amino-3-bromo-5-fluorobenzoic acid 
• 55414-45-4 (2-amino-3-bromo-5-fluorophenyl)methanol 

Downstream Products

• 953039-62-8 8-bromo-6-fluoro-quinazolin-2-ol 
• 953039-63-9 8-bromo-2-chloro-6-fluoroquinazoline 

Relevant articles and documents

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

QUINAZOLINES FOR PDK1 INHIBITION

The invention provides novel quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.